Canadian company Datinvest International (Datinvest) has signed an agreement to purchase all the outstanding shares and share capital issued by biopharmaceutical company Exxel Pharma.
Exxel Pharma shareholders will receive one common share of Datinvest in exchange for one common share of Exxel Pharma, as part of the agreement. Furthermore, all outstanding share purchase warrants of Exxel Pharma will be exchanged for share purchase warrants of Datinvest.
Exxel Pharma’s total issued and outstanding common shares and share purchase warrants will be 37.6 million and 6.3 million respectively, upon completion of the acquisition.
Datinvest will be renamed as Exxel Pharma, upon completion of the acquisition.
Datinvest also plans to raise $4m through the issuance of units in a private placement as part of the transaction.
Chinese pharmaceutical company Shanghai Pharmaceuticals Holding has signed an agreement to purchase a 26.34% share in Techpool Bio-Pharma from Japanese pharmaceutical company Takeda Pharma for CNY915m ($143.43m).
Shanghai Pharmaceuticals’ shareholding in Techpool will increase from 40.8% to 67.14% and the latter will become its subsidiary, as a result of the acquisition.
Shanghai Pharmaceuticals is executing the transaction through its subsidiary Shanghai Pharmaceuticals (HK).
Techpool Bio-Pharma is a pharmaceutical company and subsidiary of Takeda Pharma.
Chinese investment company Sunrise Bright Investment has agreed to purchase 100% equity interest in a wholly owned subsidiary of Japanese pharmaceutical company Takeda Pharma for CNY866m ($135.75m).
The transaction will provide Sunrise with an indirect equity interest of 25% in Takeda Pharma’s subsidiary Techpool Bio-Pharma.
Leerink Revelation Partners and Industry Ventures, along with other investors, have acquired AcelRx Pharmaceuticals (AcelRx) from Three Arch Partners III, Three Arch Associates III, Three Arch Partners IV, and Three Arch Associates IV.
Leerink Revelation Partners, Industry Ventures, Three Arch Partners III, Three Arch Associates III, Three Arch Partners IV, and Three Arch Associates IV, are investment firms based in the US.
The target company is a specialist pharmaceutical company based in the US.